Kim Christopher 4
4 · Apimeds Pharmaceuticals US, Inc. · Filed May 15, 2025
Insider Transaction Report
Form 4
Kim Christopher
DirectorChairman and CMO
Transactions
- Purchase
Common Stock, par value $0.01 per share
2025-05-13$1.82/sh+19,770$35,981→ 19,770 total - Purchase
Common Stock, par value $0.01 per share
2025-05-14$1.86/sh+7,730$14,378→ 27,500 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2)-(3) to this Form 4.
- [F2]These shares were sold in multiple transactions at prices ranging from $1.75 to $1.86, inclusive.
- [F3]These shares were sold in multiple transactions at prices ranging from $1.84 to $1.89, inclusive.